• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Unified Multiple System Atrophy Rating Scale: intrarater reliability.统一多系统萎缩评定量表:内部评估者信度。
Mov Disord. 2012 Nov;27(13):1683-5. doi: 10.1002/mds.25181. Epub 2012 Oct 31.
2
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS).统一多系统萎缩评定量表(UMSARS)的开发与验证
Mov Disord. 2004 Dec;19(12):1391-402. doi: 10.1002/mds.20255.
3
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).多系统萎缩(MSA)的疾病进展:欧洲多系统萎缩研究组(EMSA SG)的一项前瞻性自然史研究
Mov Disord. 2006 Feb;21(2):179-86. doi: 10.1002/mds.20678.
4
Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis.统一多系统萎缩评定量表项目的变化敏感性和以患者为中心:基于数据的分析。
Mov Disord. 2022 Jul;37(7):1425-1431. doi: 10.1002/mds.28993. Epub 2022 Mar 25.
5
The international cooperative ataxia rating scale in Machado-Joseph disease. Comparison with the unified multiple system atrophy rating scale.马查多-约瑟夫病的国际合作共济失调评定量表。与统一多系统萎缩评定量表的比较。
Mov Disord. 2007 Oct 15;22(13):1976-9. doi: 10.1002/mds.21735.
6
An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale.统一多系统萎缩评定量表的项目反应理论分析。
Parkinsonism Relat Disord. 2022 Jan;94:40-44. doi: 10.1016/j.parkreldis.2021.11.024. Epub 2021 Nov 30.
7
Reliability of the unified multiple system atrophy rating scale using the telephone.统一多系统萎缩评分量表的电话使用可靠性。
Clin Neurol Neurosurg. 2024 Feb;237:108147. doi: 10.1016/j.clineuro.2024.108147. Epub 2024 Feb 2.
8
Motor assessment of patients with multiple system atrophy: underuse of the Unified Multiple System Atrophy Rating Scale (UMSARS).多系统萎缩患者的运动评估:统一多系统萎缩评定量表(UMSARS)的使用不足。
Clin Auton Res. 2023 Apr;33(2):143-148. doi: 10.1007/s10286-023-00934-0. Epub 2023 Mar 27.
9
Longitudinal evolution of motor and non-motor symptoms in early-stage multiple system atrophy: a 2-year prospective cohort study.早期多系统萎缩症的运动和非运动症状的纵向演变:一项为期 2 年的前瞻性队列研究。
BMC Med. 2022 Nov 17;20(1):446. doi: 10.1186/s12916-022-02645-1.
10
Natural history of multiple system atrophy in the USA: a prospective cohort study.美国多系统萎缩的自然史:一项前瞻性队列研究。
Lancet Neurol. 2015 Jul;14(7):710-9. doi: 10.1016/S1474-4422(15)00058-7. Epub 2015 May 27.

引用本文的文献

1
Clinical characteristics and phenoconversion in isolated REM sleep behavior disorder: a prospective single-center study in Korea, compared with Montreal cohort.孤立性快速眼动睡眠行为障碍的临床特征与表型转换:韩国一项前瞻性单中心研究,并与蒙特利尔队列进行比较
J Clin Sleep Med. 2025 Jan 1;21(1):81-88. doi: 10.5664/jcsm.11318.
2
Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research.弥合统计学显著性与临床相关性之间的差距:运动障碍研究中报告的量表最小临床重要差异(MCID)阈值的系统评价
Heliyon. 2024 Feb 20;10(5):e26479. doi: 10.1016/j.heliyon.2024.e26479. eCollection 2024 Mar 15.
3
The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations.统一多系统萎缩评定量表:现状、批评与建议。
Mov Disord. 2022 Dec;37(12):2336-2341. doi: 10.1002/mds.29215. Epub 2022 Sep 8.
4
Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement.统一多系统萎缩评分量表作为临床试验结局指标的局限性及改进路线图。
Clin Auton Res. 2021 Apr;31(2):157-164. doi: 10.1007/s10286-021-00782-w. Epub 2021 Feb 7.
5
Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review.伴有睡眠障碍的运动障碍评定量表:一项叙述性综述。
Front Neurol. 2018 Jun 7;9:435. doi: 10.3389/fneur.2018.00435. eCollection 2018.
6
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.全球多系统萎缩研究路线图会议的建议。
Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13.

本文引用的文献

1
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.欧洲多系统萎缩的表现、诊断和治疗:欧洲多系统萎缩注册研究的最终分析。
Mov Disord. 2010 Nov 15;25(15):2604-12. doi: 10.1002/mds.23192.
2
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).米诺环素 1 年治疗多系统萎缩:对临床症状和 [(11)C](R)-PK11195 PET(MEMSA 试验)的影响。
Mov Disord. 2010 Jan 15;25(1):97-107. doi: 10.1002/mds.22732.
3
Multiple system atrophy: an update.多系统萎缩:最新进展
Lancet Neurol. 2009 Dec;8(12):1172-8. doi: 10.1016/S1474-4422(09)70288-1.
4
Intraclass correlations: uses in assessing rater reliability.组内相关系数:在评估评分者可靠性中的应用。
Psychol Bull. 1979 Mar;86(2):420-8. doi: 10.1037//0033-2909.86.2.420.
5
Second consensus statement on the diagnosis of multiple system atrophy.关于多系统萎缩诊断的第二篇共识声明。
Neurology. 2008 Aug 26;71(9):670-6. doi: 10.1212/01.wnl.0000324625.00404.15.
6
Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy.多系统萎缩尸检诊断的拟议神经病理学标准。
Neuropathol Appl Neurobiol. 2007 Dec;33(6):615-20. doi: 10.1111/j.1365-2990.2007.00907.x.
7
Potential outcome measures and trial design issues for multiple system atrophy.多系统萎缩的潜在结局指标及试验设计问题
Mov Disord. 2007 Dec;22(16):2371-7. doi: 10.1002/mds.21734.
8
Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study.生长激素治疗多系统萎缩的安全性和耐受性:一项双盲、安慰剂对照研究。
Mov Disord. 2007 Jun 15;22(8):1138-44. doi: 10.1002/mds.21501.
9
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).多系统萎缩(MSA)的疾病进展:欧洲多系统萎缩研究组(EMSA SG)的一项前瞻性自然史研究
Mov Disord. 2006 Feb;21(2):179-86. doi: 10.1002/mds.20678.
10
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS).统一多系统萎缩评定量表(UMSARS)的开发与验证
Mov Disord. 2004 Dec;19(12):1391-402. doi: 10.1002/mds.20255.

统一多系统萎缩评定量表:内部评估者信度。

The Unified Multiple System Atrophy Rating Scale: intrarater reliability.

机构信息

Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.

出版信息

Mov Disord. 2012 Nov;27(13):1683-5. doi: 10.1002/mds.25181. Epub 2012 Oct 31.

DOI:10.1002/mds.25181
PMID:23114993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6231538/
Abstract

BACKGROUND

The Unified Multiple System Atrophy Rating Scale (UMSARS) was developed to provide a surrogate measure of disease progression in multiple system atrophy. In the present study, the intrarater agreement of the motor examination part of the UMSARS was determined.

METHODS

All patients were first examined face to face, while being video-recorded, by two senior and two junior investigators. The patients' videotaped examinations were reevaluated after 3 months. Intrarater reliability for each item was analyzed by kappa statistics.

RESULTS

Overall weighted kappa (κ) values were at least substantial or excellent for all UMSARS motor examination items, except for ocular motor dysfunction, which showed only moderate intrarater agreement. Intrarater reliability was comparable between senior and junior raters, with all κ differences being ≤ 0.22.

CONCLUSIONS

The motor examination part of the UMSARS was found to have satisfactory intrarater reliability in the present cohort.

摘要

背景

统一多系统萎缩评定量表(UMSARS)旨在提供一种衡量多系统萎缩疾病进展的替代指标。本研究旨在确定 UMSARS 运动检查部分的内部一致性。

方法

所有患者均由两位高级和两位初级研究人员进行面对面检查,并录像。患者的录像检查在 3 个月后进行重新评估。采用 Kappa 统计分析各项目的内部一致性。

结果

除眼运动功能障碍外,UMSARS 运动检查的所有项目的整体加权 Kappa(κ)值均为显著或优秀,而眼运动功能障碍的内部一致性仅为中度。高级和初级评分者之间的内部一致性具有可比性,所有 κ 差异均≤0.22。

结论

本研究队列中,UMSARS 的运动检查部分具有令人满意的内部一致性。